Cybin starts trading on Nasdaq

Executive Summary

• Cybin Inc. has officially rebranded as Helus Pharma and transferred its primary stock exchange listing from NYSE American to Nasdaq, now trading under the ticker symbol HELP.
• The company is transitioning from a clinical-stage discovery entity to a commercial-ready pharmaceutical company, focusing on its proprietary Novel Serotonergic Agonists (NSAs).
• Key pipeline updates include Phase 3 development of HLP003 for major depressive disorder (with FDA Breakthrough Therapy designation) and Phase 2 development of HLP004 for generalized anxiety disorder, with key data readouts expected in 2026.

Key Details

• Corporate Identity Change: Cybin Inc. is now operating as Helus Pharma (pronounced "heal-us").
• Listing Transfer: The company’s U.S. listing has moved from NYSE American (previous ticker: CYBN) to Nasdaq under the new ticker symbol HELP.
• Canadian Listing: The company remains listed on Cboe Canada under the ticker symbol HELP.
• Legal Name Change: The company expects to seek shareholder approval at the next annual and special meeting to formally change its legal name to Helus Pharma.
• Strategic Shift: The rebrand reflects a transformation from a global clinical-stage discovery and development company to a commercial-ready pharmaceutical company.
• Pipeline Asset HLP003 (formerly CYB003):
  • Proprietary NSA in Phase 3 clinical development.
  • Indication: Adjunctive treatment of major depressive disorder.
  • Status: Received Breakthrough Therapy designation from the U.S. FDA.
• Pipeline Asset HLP004 (formerly CYB004):
  • Proprietary NSA in Phase 2 study.
  • Indication: Generalized anxiety disorder.
• Intellectual Property: The company holds over 350 filed patents, with more than 100 already granted.
• Future Outlook: Interim CEO Eric So stated that key data readouts for both HLP003 and HLP004 are expected in 2026, positioning the company for commercialization.
• Geographic Operations: The company operates in Canada, the United States, the United Kingdom, and Ireland.

Notable Quotes

• "Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004." — Eric So, Interim CEO
• "This is an exciting new chapter for the company... With key data readouts for both HLP003 and HLP004 expected in 2026, we believe we are well positioned for commercialization with the potential to significantly enhance patient outcomes, introduce innovative therapies for health care providers and deliver value to payers and shareholders." — Eric So, Interim CEO